Gel imaging system helps detect ocular-disease causing proteins

Article

British image analysis solutions manufacturer Syngene has announced that the Dyversity 2D gel imaging system is being used in Mexico to assess the proteins linked to ocular diseases.

British image analysis solutions manufacturer Syngene has announced that the Dyversity 2D gel imaging system is being used in Mexico to assess the proteins linked to ocular diseases.

The Institute of Ophthalmology (Fundación Conde de Valenciana), Mexico, uses the imaging system to view proteins stained with silver or Coomassie blue on 2D and 1D gels. Dyversity can also analyse chemiluminescent protein arrays and Western blots. The data retrieved from the gels and blots help identify which proteins cause certain ocular diseases.

Dr Victor Bautista de Lucio, Professor Researcher at the Institute, said: “We extract tears from patients with eye diseases and study the protein profiles in their tears. This means we often need an imaging system that can detect very small amounts of proteins in our 2D gels. We had an image analyser but it was not sensitive enough and sometimes we even had to go back to using manual Polaroid plates to help us visualise the protein spots, which made image analysis very difficult.”

The system will enable the institute to create good quality proteomic profiles in a range of ocular diseases.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.